Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China
· Delayed Price · Currency is CNY 51.90
-1.19 (-2.24%)
Apr 29, 2026, 3:04 PM CST
SHE:002294 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Market Capitalization | 57,859 | 55,239 | 34,481 | 35,644 | 36,225 | 30,220 | Upgrade
|
| Market Cap Growth | 58.09% | 60.20% | -3.26% | -1.60% | 19.87% | 3.71% | Upgrade
|
| Enterprise Value | 56,395 | 53,220 | 32,688 | 33,898 | 33,154 | 27,017 | Upgrade
|
| Last Close Price | 51.90 | 49.55 | 30.53 | 31.66 | 31.41 | 25.63 | Upgrade
|
| PE Ratio | 86.44 | 84.79 | 57.32 | 61.45 | 56.86 | 56.62 | Upgrade
|
| Forward PE | 73.10 | 75.65 | 51.55 | 58.32 | 54.75 | 27.88 | Upgrade
|
| PS Ratio | 12.80 | 12.69 | 8.59 | 10.59 | 10.40 | 9.88 | Upgrade
|
| PB Ratio | 6.24 | 6.10 | 3.94 | 4.43 | 4.54 | 3.76 | Upgrade
|
| P/TBV Ratio | 7.63 | 7.56 | 4.68 | 5.33 | 5.24 | 4.38 | Upgrade
|
| P/FCF Ratio | 1757.28 | 705.15 | 61.42 | 211.61 | 97.42 | 43.02 | Upgrade
|
| P/OCF Ratio | 54.16 | 52.49 | 29.07 | 42.46 | 37.32 | 25.50 | Upgrade
|
| PEG Ratio | - | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 | Upgrade
|
| EV/Sales Ratio | 12.48 | 12.23 | 8.15 | 10.07 | 9.52 | 8.83 | Upgrade
|
| EV/EBITDA Ratio | 52.25 | 51.73 | 31.24 | 37.95 | 37.95 | 33.84 | Upgrade
|
| EV/EBIT Ratio | 84.11 | 83.10 | 47.80 | 59.91 | 58.62 | 53.57 | Upgrade
|
| EV/FCF Ratio | 1712.81 | 679.37 | 58.22 | 201.24 | 89.16 | 38.46 | Upgrade
|
| Debt / Equity Ratio | 0.03 | 0.03 | 0.02 | 0.01 | 0.03 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 0.22 | 0.28 | 0.13 | 0.07 | 0.24 | 0.10 | Upgrade
|
| Debt / FCF Ratio | 7.30 | 3.70 | 0.24 | 0.38 | 0.56 | 0.11 | Upgrade
|
| Net Debt / Equity Ratio | -0.17 | -0.31 | -0.31 | -0.27 | -0.42 | -0.40 | Upgrade
|
| Net Debt / EBITDA Ratio | -1.49 | -2.72 | -2.59 | -2.40 | -3.80 | -4.03 | Upgrade
|
| Net Debt / FCF Ratio | -48.17 | -35.75 | -4.83 | -12.70 | -8.93 | -4.58 | Upgrade
|
| Asset Turnover | 0.41 | 0.40 | 0.40 | 0.35 | 0.37 | 0.38 | Upgrade
|
| Inventory Turnover | 2.08 | 2.10 | 2.28 | 2.06 | 2.08 | 2.00 | Upgrade
|
| Quick Ratio | 1.51 | 1.97 | 3.09 | 3.40 | 2.56 | 3.88 | Upgrade
|
| Current Ratio | 2.34 | 2.28 | 3.62 | 4.07 | 2.94 | 4.35 | Upgrade
|
| Return on Equity (ROE) | 7.41% | 7.33% | 7.20% | 7.25% | 7.92% | 7.75% | Upgrade
|
| Return on Assets (ROA) | 3.80% | 3.68% | 4.30% | 3.69% | 3.72% | 3.90% | Upgrade
|
| Return on Invested Capital (ROIC) | 9.51% | 10.37% | 10.95% | 9.69% | 10.60% | 9.13% | Upgrade
|
| Return on Capital Employed (ROCE) | 7.00% | 6.90% | 7.30% | 6.60% | 6.90% | 6.10% | Upgrade
|
| Earnings Yield | 1.17% | 1.18% | 1.75% | 1.63% | 1.76% | 1.77% | Upgrade
|
| FCF Yield | 0.06% | 0.14% | 1.63% | 0.47% | 1.03% | 2.33% | Upgrade
|
| Dividend Yield | 1.04% | 1.11% | 1.64% | 1.58% | 1.59% | 1.56% | Upgrade
|
| Payout Ratio | 82.75% | 85.68% | 90.77% | 94.71% | 69.25% | 2.91% | Upgrade
|
| Buyback Yield / Dilution | -1.13% | -0.83% | 0.13% | -1.55% | -2.90% | -5.23% | Upgrade
|
| Total Shareholder Return | -0.12% | 0.28% | 1.77% | 0.02% | -1.31% | -3.67% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.